Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy-Reference-Cited by-同舟云学术

Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy

Published:2019-10 Issue:5 Volume:8 Page:593-604
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl. Lung Cancer Res.

Author:

Taugner Julian,Käsmann Lukas,Eze Chukwuka,Dantes Maurice,Roengvoraphoj Olarn,Gennen Kathrin,Karin Monika,Petruknov Oleg,Tufman Amanda,Belka Claus,Manapov Farkhad

Publisher

AME Publishing Company

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis;Strahlentherapie und Onkologie;2023-11-17

2. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis;Journal of Cancer Research and Clinical Oncology;2022-08-02

3. Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study;Translational Lung Cancer Research;2022-07

4. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data;Drugs - Real World Outcomes;2022-06-03

5. Importance of Prognostic Factors in Lung Cancer;Medical Radiology;2022